Drugs / MDGN201 TARGTEPO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02117427 | May 2014 → Jun 2016 | end stage renal failure | Aevi Genomic Medicine, LLC, a Cerecor company | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDGN201 TARGTEPO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02117427 ↗ |